| Long term survivors in severe aplastic anemia: standard mortality rates now comparable to controls? |
|
Haematologica |
Aplastic Anemia |
| Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
